Eli Lilly and Company raised its quarterly dividend in 2025 as revenue from GLP-1 receptor agonist drugs Mounjaro and Zepbound continued to exceed Wall Street forecasts. The pharmaceutical giant now pays shareholders $0.87 per share quarterly, representing a forward yield near 0.95 percent at current prices. While the yield is modest, the dividend growth trajectory and underlying drug pipeline strength make LLY a compelling holding for investors seeking exposure to the fastest-growing segment in healthcare.
The setup: GLP-1 drugs reshape Eli Lilly’s revenue
Eli Lilly’s GLP-1 franchise generated more than $18 billion in revenue during fiscal 2024, up from approximately $5 billion in 2023. Mounjaro, approved for type 2 diabetes, and Zepbound, approved for obesity, have become the dominant products in a market expected to exceed $100 billion globally by 2030. The company’s manufacturing capacity expansions in North Carolina and Indiana are designed to meet demand that currently outstrips supply.
The stock has risen more than 350 percent since the first GLP-1 obesity data readouts in 2021, making Eli Lilly the largest healthcare company by market capitalization in the United States. Despite the appreciation, analysts continue to cite pipeline optionality in Alzheimer’s disease, oncology, and next-generation incretin therapies as underappreciated catalysts.
Key numbers for Eli Lilly investors
| Metric | Value |
|---|---|
| Ticker | LLY |
| Quarterly dividend | $0.87 |
| Forward yield | ~0.95% |
| Payout ratio | ~22% |
| Market cap | ~$815 billion |
| 2024 GLP-1 revenue | $18 billion+ |
| Consecutive years of dividend growth | 11 years |
Dividend sustainability and growth outlook
Eli Lilly’s dividend payout ratio sits near 22 percent of earnings, leaving substantial room for continued increases even if GLP-1 revenue growth moderates. The company has raised its dividend annually for 11 consecutive years, a streak management has signaled it intends to maintain. Free cash flow generation of approximately $12 billion in 2024 provides coverage for both the dividend and aggressive capital allocation toward manufacturing and research.
Compared to traditional pharmaceutical dividend stocks like Johnson & Johnson and Merck, Eli Lilly offers a lower starting yield but faster dividend growth. A retiree with $100,000 invested in LLY at the beginning of 2023 would have collected approximately $950 in annual dividend income initially. With the two dividend increases since then, that same position now generates roughly $1,180 annually, a 24 percent income increase in two years.
What to watch for Eli Lilly shareholders
Regulatory scrutiny of GLP-1 drugs is intensifying as policymakers debate coverage expansion under Medicare and Medicaid. Any restriction on reimbursement could temper revenue growth forecasts. Supply constraints have also limited near-term sales, though the company’s manufacturing buildout should resolve bottlenecks by late 2025.
Competition from Novo Nordisk’s Wegovy and Ozempic remains fierce, and both companies are racing to develop oral GLP-1 formulations that could disrupt the injectable market. Patent litigation around GLP-1 compounds is another risk factor that could affect exclusivity timelines. Investors should monitor FDA advisory committee schedules and Medicare coverage determinations for signals on pricing power.
Analyst outlook for Eli Lilly
Analysts at Morgan Stanley maintain an “Overweight” rating on LLY with a price target of $1,100, citing GLP-1 revenue durability and manufacturing scale as competitive moats. Goldman Sachs assigns a “Buy” rating with a target of $1,075, noting that pipeline optionality in Alzheimer’s treatment is not fully reflected in current valuation. Stephens analysts point to the company’s ability to raise prices in a deflationary pharmaceutical environment as a distinguishing factor.
The consensus view among surveyed firms suggests that Eli Lilly’s current valuation assumes GLP-1 revenue growth through 2028, with limited credit for earlier-stage programs. Any positive clinical readout from the Alzheimer’s pipeline could reset expectations higher.
Common mistakes income investors make with growth stocks
Some conservative investors avoid stocks with yields below 2 percent, dismissing them as inadequate for income needs. Eli Lilly demonstrates that dividend growth can compensate for low initial yields over multi-year holding periods. Another common error is concentrating too heavily in a single sector; pharmaceutical exposure should represent only a portion of a diversified income portfolio.
Timing purchases around earnings volatility is another behavioral trap. Eli Lilly shares have experienced 10 to 15 percent swings around clinical trial readouts, creating entry points for patient investors but anxiety for those who buy at local peaks. Dollar-cost averaging into positions reduces timing risk.
Bottom line
Eli Lilly offers a rare combination of dividend growth, earnings momentum, and sector leadership in a healthcare market that favors obesity and diabetes treatment. The current yield is modest, but the payout ratio and cash flow generation support continued increases. Income investors willing to accept lower near-term yields in exchange for growth may find LLY suitable as a satellite position within a diversified healthcare allocation.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
